NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $9.62 +0.46 (+5.02%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$9.67 +0.05 (+0.56%) As of 05/27/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Upstream Bio Stock (NASDAQ:UPB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Upstream Bio alerts:Sign Up Key Stats Today's Range$9.23▼$9.9050-Day Range$6.07▼$10.1552-Week Range$5.14▼$29.46Volume660,442 shsAverage Volume329,470 shsMarket Capitalization$517.50 millionP/E RatioN/ADividend YieldN/APrice Target$56.50Consensus RatingBuy Company OverviewUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Read More… Upstream Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreUPB MarketRank™: Upstream Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 619th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingUpstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUpstream Bio has received no research coverage in the past 90 days.Read more about Upstream Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.Read more about Upstream Bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for UPB. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUpstream Bio does not currently pay a dividend.Dividend GrowthUpstream Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for UPB. News and Social Media2.8 / 5News Sentiment0.99 News SentimentUpstream Bio has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Upstream Bio this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Upstream Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Upstream Bio's insider trading history. Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address UPB Stock News HeadlinesUpstream Bio names new chief technology officerMay 21, 2025 | investing.comUpstream Bio Appoints Stacy Price As CTOMay 21, 2025 | nasdaq.comTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.May 28, 2025 | Paradigm Press (Ad)Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical OperationsMay 21, 2025 | nasdaq.comUpstream Bio Appoints Stacy Price as Chief Technology OfficerMay 20, 2025 | globenewswire.comUpstream Bio Advances Verekitug in Clinical TrialsMay 7, 2025 | tipranks.comUpstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical ProgramsMay 6, 2025 | globenewswire.comUpstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentApril 17, 2025 | seekingalpha.comSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $16.44 on January 1st, 2025. Since then, UPB shares have decreased by 41.5% and is now trading at $9.62. View the best growth stocks for 2025 here. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The firm earned $0.57 million during the quarter, compared to the consensus estimate of $0.71 million. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO. When did the company's lock-up period expire? Upstream Bio's lock-up period expired on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Upstream Bio's major shareholders? Top institutional shareholders of Upstream Bio include Wellington Management Group LLP (2.44%), Siren L.L.C. (1.47%), Siren L.L.C. (1.47%) and Nantahala Capital Management LLC (1.11%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc. View institutional ownership trends. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2025Today5/27/2025Next Earnings (Estimated)6/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Target$56.50 High Stock Price Target$75.00 Low Stock Price Target$38.00 Potential Upside/Downside+487.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.30 million Price / Sales225.39 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,794,000Free FloatN/AMarket Cap$517.50 million OptionableN/A BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:UPB) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.